■我们试图评估生长分化因子(GDF)-15治疗抑制上皮间质转化(EMT)和减轻转化生长因子β2(TGFβ2)诱导的晶状体混浊的功效。
■为了测试GDF-15是否是防止EMT的分子,我们用GDF-15在神经祖细胞中预处理培养物,视网膜色素上皮细胞,和晶状体上皮细胞,然后用促进EMT的因子治疗,分别为GDF-11和TGFβ2。为了进一步研究GDF-15减轻晶状体混浊的功效,我们使用小鼠晶状体外植体培养来模拟继发性白内障。我们用GDF-15预处理晶状体培养物,然后加入TGFβ2以形成晶状体混浊(每组n=3)。Westernblot和定量逆转录聚合酶链反应(qRT-PCR)检测EMT蛋白和基因表达,分别。
■在细胞培养中,GDF-15预处理显著减弱了用GDF-11或TGFβ2处理诱导的培养细胞中的EMT标记表达。在晶状体外植体培养中,GDF-15预处理还减少了由暴露于TGFβ2引起的小鼠晶状体不透明度。
■我们的结果表明,GDF-15可以缓解TGFβ2诱导的EMT,并且是减缓或预防白内障手术后后囊混浊(PCO)进展的潜在治疗剂。
■白内障是全球失明的主要原因,目前唯一的治疗包括手术摘除晶状体和更换人工晶状体。然而,PCO,也称为继发性白内障,是白内障手术后常见的并发症。开发减缓PCO进展的佐剂将有益于前部并发症领域。
UNASSIGNED: We sought to evaluate the efficacy of growth differentiation factor (GDF)-15 treatment for suppressing epithelial-mesenchymal transition (EMT) and alleviating transforming growth factor β2 (TGFβ2)-induced lens opacity.
UNASSIGNED: To test whether GDF-15 is a molecule that prevents EMT, we pretreated the culture with GDF-15 in neural progenitor cells, retinal pigment epithelial cells, and lens epithelial cells and then treated with factors that promote EMT, GDF-11, and TGFβ2, respectively. To further investigate the efficacy of GDF-15 on alleviating lens opacity, we used mouse lens explant culture to mimic secondary cataracts. We pretreated the lens culture with GDF-15 and then added TGFβ2 to develop lens opacity (n = 3 for each group). Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to measure EMT protein and gene expression, respectively.
UNASSIGNED: In cell culture, GDF-15 pretreatment significantly attenuated EMT marker expression in cultured cells induced by treatment with GDF-11 or TGFβ2. In the lens explant culture, GDF-15 pretreatment also reduced mouse lens opacity induced by exposure to TGFβ2.
UNASSIGNED: Our results indicate that GDF-15 could alleviate TGFβ2-induced EMT and is a potential therapeutic agent to slow or prevent posterior capsular opacification (PCO) progression after cataract surgery.
UNASSIGNED: Cataracts are the leading cause of blindness worldwide, with the only current treatment involving surgical removal of the lens and replacement with an artificial lens. However, PCO, also known as secondary cataract, is a common complication after cataract surgery. The development of an adjuvant that slows the progression of PCO will be beneficial to the field of anterior complications.